Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease
- PMID: 3417226
- DOI: 10.1002/hep.1840080514
Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease
Abstract
In order to study the relationship between amiodarone-induced hepatic phospholipidosis and liver disease, liver biopsies obtained from 13 patients treated with amiodarone for 4 months to 15 years were investigated by light and electron microscopy. Light microscopy showed pseudoalcoholic liver lesions that were probably related to amiodarone in four cases, various alterations (i.e. cirrhosis, three cases; steatosis and fibrosis, two cases; chronic venous congestion, one case; acute hepatitis, one case) that could be explained by another cause than amiodarone in seven cases and normal liver in two cases. In all cases, electron microscopy showed intralysosomal myelin figures suggestive of phospholipidosis. These myelin figures were associated with intralysosomal electron-dense deposits. In the four cases in which analysis by electron microprobe was performed, it demonstrated large amounts of iodine in the electron-dense deposit-containing lysosomes, indicating the accumulation of amiodarone. These results show that hepatic phospholipidosis is constantly observed in amiodarone-treated patients, whether or not pseudoalcoholic liver lesions are present. This phospholipidosis, which could be only a morphological marker of intrahepatic accumulation of the drug, should not therefore be considered grounds for attributing liver disease to the drug.
Similar articles
-
Amiodarone-induced hepatic phospholipidosis: correlation of morphological and biochemical findings in an animal model.Hepatology. 1988 May-Jun;8(3):591-8. doi: 10.1002/hep.1840080326. Hepatology. 1988. PMID: 3371876
-
Histopathologic analysis of suspected amiodarone hepatotoxicity.Hum Pathol. 1990 Jan;21(1):59-67. doi: 10.1016/0046-8177(90)90076-h. Hum Pathol. 1990. PMID: 2403975 Review.
-
Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies.Gastroenterology. 1984 May;86(5 Pt 1):926-36. Gastroenterology. 1984. PMID: 6706074
-
Increased hepatic density and phospholipidosis due to amiodarone.AJR Am J Roentgenol. 1985 Mar;144(3):541-6. doi: 10.2214/ajr.144.3.541. AJR Am J Roentgenol. 1985. PMID: 3871563
-
Double Hit of Hydroxichloroquine and Amiodarone Induced Renal Phospholipidosis in a Patient with Monoclonal Gammopathy and Sclerodermiform Syndrome: A Case Report and Review of the Literature.Med Sci (Basel). 2024 May 15;12(2):25. doi: 10.3390/medsci12020025. Med Sci (Basel). 2024. PMID: 38804381 Free PMC article. Review.
Cited by
-
Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key.Int J Mol Sci. 2023 Jun 27;24(13):10718. doi: 10.3390/ijms241310718. Int J Mol Sci. 2023. PMID: 37445895 Free PMC article. Review.
-
Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2.Science. 2021 Jul 30;373(6554):541-547. doi: 10.1126/science.abi4708. Epub 2021 Jun 22. Science. 2021. PMID: 34326236 Free PMC article.
-
Lupus Nephritis and Hydroxychloroquine-Associated Zebra Bodies: Not Just in Fabry Disease.Kidney Med. 2021 Mar 18;3(3):442-446. doi: 10.1016/j.xkme.2021.01.006. eCollection 2021 May-Jun. Kidney Med. 2021. PMID: 34136790 Free PMC article.
-
Phospholipidosis is a shared mechanism underlying the in vitro antiviral activity of many repurposed drugs against SARS-CoV-2.bioRxiv [Preprint]. 2021 Mar 24:2021.03.23.436648. doi: 10.1101/2021.03.23.436648. bioRxiv. 2021. PMID: 33791693 Free PMC article. Preprint.
-
Other types of diffuse liver disease: is there a way to do it?Abdom Radiol (NY). 2020 Nov;45(11):3425-3443. doi: 10.1007/s00261-020-02530-6. Abdom Radiol (NY). 2020. PMID: 32306241 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical